Breaking News
All the ways Iran beat Trump into submission
EXCLUSIVE: Top FBI Whistleblower Says The Supposed Terror Plot Targeting The White House...
US Workers Receive Smallest Share of Corporate Profits Since 1948
The International Moth is a development sailing class known for decades of innovation...
Top Tech News
Heads up: Apparently the government is hiding cameras inside fake utility boxes
Sodium Batteries And EVs That Power The Grid: Inside GM's Big Energy Push
NUCLEAR ENGINE - UNLIMITED LUXURY - 20 YEARS WITHOUT REFUELING
China Unveils Nuclear-Powered Floating Hub For Green Shipping
China Launches World's 1st Commercial Brain Chip, Beating Elon Musk's Neuralink!
Modular next-gen US nuclear reactor goes critical
How EMF's cause disease
This Company Will Add Phone, AirPod, and Smartwatch Trackers to License Plate Readers
Elon Details SpaceX AI Data Center in Space Details and Roadmap
5-in-1 miniature surgical robot is the size of a seed 
DARPA Nucleic Technology Funded to Get Virus Response to 1-60 Days
The P3 teams are developing technologies to deliver antibodies using nucleic acid technology, and achieve sufficient serum concentrations of the antibodies for protection against the pathogen within three days after administration.
DARPA has programs for Pandemic Prevention Platform, Nucleic Acids On-Demand Worldwide (NOW), and PReemptive Expression of Protective Alleles and Response Elements (PREPARE) programs.
Nucleic Acids On-Demand Worldwide (NOW)
The goal of the NOW program is to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA) in less than 24 hours. The developed platform should be a resilient, mobile, readily accessible nucleic acid MCM manufacturing capability that enables immediate threat response anywhere the military operates with minimal user intervention.